{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:21:30Z","timestamp":1791469290509,"version":"4.3.4"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The treatment of acute and chronic graft-versus-host disease (GvHD) remains a challenge, particularly in cases of steroid-refractory GvHD. The management of GvHD varies between institutions, and little is known regarding the practices in different regions of the world. Thus, the Worldwide Network for Blood and Marrow Transplantation has developed a questionnaire to understand the current practices of GvHD management in the Eastern Mediterranean (EM) region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>The questionnaire had 46 items and was distributed electronically to transplant centers in the EM region. Responses were received between December 2022 and June 2023. The questionnaire addressed the management of acute and chronic GvHD for both newly diagnosed and refractory cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The questionnaire was completed by 30 programs across 26 institutions located in 11 countries. For patients with newly diagnosed acute GvHD, most programs reported the use of systemic steroids for initial treatment, with doses selected based on the severity of the presentation: the equivalent of 1\u2009mg\/kg\/day of prednisone for grade IIa and 2\u2009mg\/kg\/day for grade IIb. In addition to steroids, most programs continued immunosuppressive therapy or reintroduced it if GvHD developed after its cessation. For patients who were refractory to steroids, ruxolitinib was the most frequently selected second-line treatment, chosen by 80% of the programs, followed by calcineurin inhibitors (47%), high-dose steroids (&gt;2\u2009mg\/kg, 43%), mycophenolate mofetil (MMF, 40%), and extracorporeal photopheresis (ECP, 40%). On the other hand, for patients with newly diagnosed chronic GvHD, systemic steroids are used for the initial management of mild chronic GvHD not accessible by topical treatment and moderate to severe disease, with the most commonly used initial dose being the equivalent of 0.5 to 1 and &gt;1\u2009mg\/kg\/day of prednisone, respectively. More than two-thirds of the programs use another agent in addition to steroids in patients who develop moderate\/severe chronic GvHD while off immunosuppressive therapy. For patients with steroid-refractory chronic GvHD, most programs selected multiple options in the second-line setting, with the most frequently selected options being ruxolitinib (77%), calcineurin inhibitors (68%), MMF (53%), imatinib (53%), ECP (50%), rituximab (47%), and ibrutinib (40%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results demonstrated that GvHD management practices in the EM region generally align with current guidelines. However, the results highlight that access to clinical trials and multidisciplinary support teams remains limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/hemoncstem.hemoncstem-d-25-00005","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T07:01:32Z","timestamp":1750402892000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Acute and chronic graft-versus-host disease treatment and management in the Eastern Mediterranean region: A Worldwide Network for Blood and Marrow Transplantation survey"],"prefix":"10.4103","volume":"18","author":[{"given":"Ibrahim N.","family":"Muhsen","sequence":"first","affiliation":[{"name":"Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[{"name":"University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[{"name":"HopitalPiti\u00e9 Salp\u00eatri\u00e8re, APHP, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Cancer Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegard T.","family":"Greinix","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"El Fakih","sequence":"additional","affiliation":[{"name":"Hematology, Stem Cell Transplantation and Cellular Therapy Department, Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour Ben","family":"Abdeljelil","sequence":"additional","affiliation":[{"name":"Centre National de Greffe de Moelle Osseuse, Tunis, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraheem","family":"Abosoudah","sequence":"additional","affiliation":[{"name":"King Faisal Specialist Hospital and Research Center-Jeddah, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Alamoudi","sequence":"additional","affiliation":[{"name":"King Abdulaziz Medical City, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"Albeihany","sequence":"additional","affiliation":[{"name":"King Faisal Specialist Hospital & Research Centre-Madinah, Madinah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Ahmed","family":"Al Daama","sequence":"additional","affiliation":[{"name":"King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hamad","family":"Alshahrani","sequence":"additional","affiliation":[{"name":"Prince Sultan Military Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem","family":"Alshemmari","sequence":"additional","affiliation":[{"name":"Kuwait Cancer Center, Kuwait, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtadha","family":"Al-Khabori","sequence":"additional","affiliation":[{"name":"Sultan Qaboos University, Muscat, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlam","family":"Almasari","sequence":"additional","affiliation":[{"name":"King Faisal Specialist Hospital and Research Center-Jeddah, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhakim","family":"Al Rawas","sequence":"additional","affiliation":[{"name":"Sultan Qaboos University, Muscat, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat","family":"Askar","sequence":"additional","affiliation":[{"name":"Health Sector and College of Medicine, Qatar University, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed-Amine","family":"Bekadja","sequence":"additional","affiliation":[{"name":"Hematology and Cell Therapy, EHU 1st Novembre 1954 Bir el Djir Usto, Oran, Algeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Benakli","sequence":"additional","affiliation":[{"name":"Pierre and Marie Curie Center; University of Health Sciences, Algiers, Algeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munira","family":"Borhany","sequence":"additional","affiliation":[{"name":"National Institute of Blood Disease, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria El","family":"Kababri","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology Center of Rabat, Mohamed V University, Rabat, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Halahleh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, King Hussein Cancer Centre Adult BMT Program, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Ali","family":"Hamidieh","sequence":"additional","affiliation":[{"name":"Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hammad","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Department, National Cancer Institute, Cairo University and Children\u2019s Cancer Hospital Egypt (CCHE-57357), Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Makassed Hospital and Middle East Institute of Health, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solaf","family":"Kanfar","sequence":"additional","affiliation":[{"name":"King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Hamed","family":"Khalaf","sequence":"additional","affiliation":[{"name":"Maadi Armed Forces Medical Compound, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Marei","sequence":"additional","affiliation":[{"name":"King Fahad Medical Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ayaz","family":"Mir","sequence":"additional","affiliation":[{"name":"Shifa International Hospital, Islamabad, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Monagel","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud bin Abdul-Aziz University for Health Sciences, Jeddah, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Jeddah, Saudi Arabia"},{"name":"Department of Pediatric Oncology, King Abdullah Specialized Children Hospital, Ministry of the National Guard Health Affairs, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Quessar","sequence":"additional","affiliation":[{"name":"H\u00f4pital Universitaire Cheikh Zaid, Rabat, Morocco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawad","family":"Rihani","sequence":"additional","affiliation":[{"name":"King Hussein Cancer Centre, Department of Pediatrics, Pediatric BMT Program, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munira","family":"Shabbir-Moosajee","sequence":"additional","affiliation":[{"name":"Aga Khan University Hospital, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Shaheen","sequence":"additional","affiliation":[{"name":"Hematology, Stem Cell Transplantation and Cellular Therapy Department, Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almetwaly Mohamed","family":"Sultan","sequence":"additional","affiliation":[{"name":"Nasser Institute for Research and Treatment, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Vaezi","sequence":"additional","affiliation":[{"name":"Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Rondelli","sequence":"additional","affiliation":[{"name":"University of Illinois Hospital & Health Sciences System, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickey Boon Chai","family":"Koh","sequence":"additional","affiliation":[{"name":"St George\u2019s University Hospitals, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zina","family":"Peric","sequence":"additional","affiliation":[{"name":"School of Medicine, University Hospital Centre Zagreb, University of Zagreb, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naeem","family":"Chaudhri","sequence":"additional","affiliation":[{"name":"Hematology, Stem Cell Transplantation and Cellular Therapy Department, Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"Hematology, Stem Cell Transplantation and Cellular Therapy Department, Oncology Center, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"R1-20250728","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat Rev Dis Primers"},{"issue":"(10)","key":"R2-20250728","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/ajh.27040","article-title":"Updates in chronic graft\u2010versus\u2010host disease management","volume":"98","author":"Malard","year":"2023","journal-title":"Am J Hematol"},{"issue":"(1)","key":"R3-20250728","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/hematology.2021000301","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"(2)","key":"R4-20250728","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"(3)","key":"R5-20250728","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"(19)","key":"R6-20250728","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"(21)","key":"R7-20250728","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"(10)","key":"R8-20250728","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"(17)","key":"R9-20250728","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.20.02754","article-title":"ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease","volume":"39","author":"Jagasia","year":"2021","journal-title":"J Clin Oncol"},{"issue":"(22)","key":"R10-20250728","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"(5)","key":"R11-20250728","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-020-0804-2","article-title":"Treatment and unmet needs in steroid-refractory acute graft-versus-host disease","volume":"34","author":"Malard","year":"2020","journal-title":"Leukemia"},{"issue":"(7)","key":"R12-20250728","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.bbmt.2019.03.003","article-title":"Changes in immunosuppressive treatment of chronic graft-versus-host disease: comparison of 2 surveys within allogeneic hematopoietic stem cell transplant centers in Germany, Austria, and Switzerland","volume":"25","author":"Wolff","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"(6)","key":"R13-20250728","doi-asserted-by":"crossref","first-page":"504.e1","DOI":"10.1016\/j.jtct.2020.12.027","article-title":"Epidemiology and treatment of chronic graft-versus-host disease post-allogeneic hematopoietic cell transplantation: a US claims analysis.","volume":"27","author":"Bachier","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"(6)","key":"R14-20250728","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2014.118471","article-title":"Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial","volume":"100","author":"Mielcarek","year":"2015","journal-title":"Haematologica"},{"key":"R15-20250728","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"(11)","key":"R16-20250728","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT\u2212NIH\u2212CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"(1)","key":"R17-20250728","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2012.09131.x","article-title":"Organ\u2010specific management and supportive care in chronic graft\u2010versus\u2010host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"issue":"(1)","key":"R18-20250728","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1182\/hematology.2021000302","article-title":"What else do I need to worry about when treating graft-versus-host disease?","volume":"2021","author":"El-Jawahri","year":"2021","journal-title":"Hematology"},{"issue":"(7)","key":"R19-20250728","first-page":"2288","article-title":"Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation","volume":"92","author":"Van Lint","year":"1998","journal-title":"Blood"},{"issue":"(2)","key":"R20-20250728","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2013.107","article-title":"Prophylaxis and treatment of GvHD: EBMT-ELN working group recommendations for a standardized practice","volume":"49","author":"Ruutu","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"(13)","key":"R21-20250728","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1182\/blood-2008-07-168401","article-title":"Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes","volume":"113","author":"Mielcarek","year":"2009","journal-title":"Blood"},{"key":"R22-20250728","doi-asserted-by":"crossref","first-page":"954268","DOI":"10.3389\/fimmu.2022.954268","article-title":"Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: a meta-analysis","volume":"13","author":"Fan","year":"2022","journal-title":"Front Immunol"},{"issue":"(7)","key":"R23-20250728","doi-asserted-by":"crossref","first-page":"e0271979","DOI":"10.1371\/journal.pone.0271979","article-title":"Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: systematic review and meta-analysis of randomised and non-randomised studies","volume":"17","author":"Zhang","year":"2022","journal-title":"PLoS One"},{"issue":"(2)","key":"R24-20250728","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"issue":"(8)","key":"R25-20250728","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/oncolo\/oyac076","article-title":"Recent FDA approvals in the treatment of graft-versus-host disease","volume":"27","author":"Martini","year":"2022","journal-title":"Oncologist"},{"issue":"(11)","key":"R26-20250728","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood.2021014448","article-title":"Three US Food and Drug Administration-approved therapies for chronic GvHD","volume":"139","author":"Zeiser","year":"2022","journal-title":"Blood"},{"issue":"(3)","key":"R27-20250728","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41409-023-02174-2","article-title":"ECP versus ruxolitinib in steroid-refractory chronic GvHD-a retrospective study by the EBMT transplant complications working party","volume":"59","author":"Penack","year":"2024","journal-title":"Bone Marrow Transplant"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-25-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:05:37Z","timestamp":1787760337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-25-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-25-00005","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2025-02-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}